C12Y 207/11021
Polo kinase
Official title: Polo kinase (2.7.11.21)
C12Y207/11021 (Polo kinase) appears on 19 US grants and 28 published applications in this corpus.
Search patents in C12Y- Granted patents
- 19
- Published applications
- 28
- Assignees
- 21
- Inventors
- 71
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 2 |
| 2009 | 1 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 3 |
| 2015 | 3 | 2 |
| 2016 | 1 | 5 |
| 2017 | 3 | 1 |
| 2018 | 3 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 2 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 2 | 5 |
| 2025 | 1 | 0 |
| 2026 | 3 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- PLK1 target phosphorylation status and treatment of cancer with PLK1 inhibitors16 Jun 2026US 12,655,462 B2Cardiff Oncology, Inc.
- Lipid particles for nucleic acid delivery and clinical applications of same5 May 2026US 12,616,662 B2Ramot at Tel-Aviv University Ltd.
- Growth inhibitor10 Feb 2026US 12,545,896 B2Orizuru Therapeutics, Inc.
- Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells18 Feb 2025US 12,228,572 B2The First Hospital of China Medical University
- HLA-A2 subtype-specific PLK1-derived epitope inducing antigen-specific t cell immune response to PLK1 protein6 Aug 2024US 12,054,752 B2The Catholic University of Korea Industry-Academic Cooperation Foundation
- Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors1 Oct 2026US 2026/0297646 A1Cardiff Oncology, Inc.
- Drug screening method based on drug discovery concept of cancer cell proliferation inhibition induced by disruption of chromosome regulation due to plk1 kinase activation18 Jun 2026US 2026/0168005 A1Japanese Foundation for Cancer Research
- Ph-responsive lipid derivative14 Nov 2024US 2024/0374733 A1Nof Corporation
- Novel peptides and uses thereof for treating cancer12 Sep 2024US 2024/0301002 A1Symthera Canada Ltd.
- Biomarker of hiv or siv infected cells and its application8 Aug 2024US 2024/0264171 A1The First Hospital of China Medical University
Most cited
By later US patents
- Silencing of polo-like kinase expression using interfering RNA20US 9,006,191 B2Protiva Biotherapeutics, Inc. · 2015
- Fragment ligated inhibitors selective for the polo box domain of PLK14US 10,067,131 B2University of South Carolina · 2018
- Fragment ligated inhibitors selective for the polo box domain of PLK13US 9,175,357 B2University of South Carolina · 2015
- Small interference RNAs, uses thereof and method for inhibiting the expression of plk1 gene2US 9,328,348 B2Suzhou Ribo Life Science Co., Ltd. · 2016
- Therapeutics with conformationally restricted monomers1US 10,023,863 B2Marina Biotech, Inc. · 2018